NYSE American - Delayed Quote USD

Protalix BioTherapeutics, Inc. (PLX)

1.6700

+0.0100

+(0.60%)

At close: May 14 at 4:00:00 PM EDT

1.6800

+0.01

+(0.60%)

Pre-Market: 5:57:34 AM EDT

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York.

PR Newswire 23 hours ago

PLX
+0.60%
PLX: First Quarter Results

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT First Quarter 2025 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 1Q:25 financial and operational results in a May 9 th , 2025 press release and in its Form 10-Q filing. The reports were followed by a conference call which discussed recent achievements, clinical updates and financial

Zacks Small Cap Research 2 days ago

PLX
+0.60%
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ...

Protalix BioTherapeutics Inc (PLX) reports a 170% revenue increase and advances in clinical trials, despite rising costs and competitive challenges.

GuruFocus.com 5 days ago

PLX
+0.60%
Protalix: Q1 Earnings Snapshot

HACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. PLX) on Friday reported a loss of $3.6 million in its first quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had a loss of 5 cents.

Associated Press Finance 5 days ago

PLX
+0.60%
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update.

PR Newswire 5 days ago

PLX
+0.60%
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025.

PR Newswire 9 days ago

PLX
+0.60%
Top Penny Stocks To Watch In April 2025

As the U.S. stock market experiences a surge, driven by positive earnings reports and anticipation of tariff news, investors are paying close attention to potential opportunities across various sectors. For those willing to explore beyond established giants, penny stocks—often representing smaller or newer companies—remain an intriguing option. Despite being considered somewhat outdated, these stocks can still offer significant growth potential when backed by strong financials and sound...

Simply Wall St. 20 days ago

SGMT

PLX
+0.60%

ORGN
Protalix BioTherapeutics And 2 Other Promising Penny Stocks

As U.S. stock markets continue to recover, with major indices closing higher for the third consecutive day, investors are cautiously optimistic about the potential easing of tariffs and its impact on economic growth. In such a climate, identifying promising investment opportunities requires a keen eye for companies that combine financial resilience with growth potential. Though penny stocks might seem like a thing of the past, they still offer significant opportunities when backed by solid...

Simply Wall St. last month

NRDY

PLX
+0.60%
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025.

PR Newswire last month

PLX
+0.60%
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?

We recently published a list of 12 High Growth Low Debt Stocks to Invest in Now. In this article, we are going to take a look at where Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) stands against other high growth low debt stocks to invest in now. The global financial markets are experiencing heightened volatility, influenced by a […]

Insider Monkey last month

PLX
+0.60%
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025

RALEIGH, NC / ACCESS Newswire / March 21, 2025 /iAccess Alpha's Virtual Best Ideas Spring Investment Conference will take place on March 25-26, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and ...

ACCESS Newswire last month

ACCS

BCHT

IDN
PLX: 2024 Results

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT 2024 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 2024 financial and operational results in a March 17 th , 2024 press release and in its Form 10-K filing. The reports were followed by a conference call which discussed recent achievements, clinical updates and financial performance. In

Zacks Small Cap Research last month

PLX
+0.60%
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ...

Protalix BioTherapeutics Inc (PLX) reports significant revenue growth driven by partnerships, but faces challenges with declining net income and reduced R&D services revenue.

GuruFocus.com last month

PLX
+0.60%
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.

PR Newswire last month

PLX
+0.60%
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025.

PR Newswire 2 months ago

PLX
+0.60%
3 US Penny Stocks With Market Caps Under $400M To Watch

As the U.S. stock market edges closer to record highs, driven by a rally in tech stocks and easing trade concerns, investors are exploring diverse opportunities across various sectors. Penny stocks, often associated with smaller or emerging companies, remain an intriguing area for those seeking potential growth at a lower entry cost. Despite their historical reputation as speculative investments, penny stocks backed by strong financials can offer unique value propositions and growth potential...

Simply Wall St. 3 months ago

BARK

BARK-WS

GPRO
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City.

PR Newswire 3 months ago

PLX
+0.60%
PLX: Revisiting the Thesis

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates in development. Its products are produced and manufactured using the ProCellEx platform

Zacks Small Cap Research 3 months ago

PLX
+0.60%
US Penny Stocks: Arbe Robotics And 2 More Promising Picks

As the U.S. stock market navigates a period of volatility marked by rising Treasury yields and shifting economic data, investors are increasingly exploring alternative investment avenues. Penny stocks, often representing smaller or newer companies, continue to attract interest due to their potential for value and growth that larger firms might overlook. Despite being an older term, penny stocks remain relevant for those seeking opportunities in under-the-radar companies with promising...

Simply Wall St. 4 months ago

PLX
+0.60%

ARBE

ARBEW
Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders.

PR Newswire 4 months ago

PLX
+0.60%

Performance Overview

Return	PLX	S&P 500 (^GSPC)
YTD	-11.17%	+0.19%
1-Year	+43.97%	+12.31%
3-Year	+57.55%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

PLX: First Quarter Results

Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ...

Protalix: Q1 Earnings Snapshot

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Top Penny Stocks To Watch In April 2025

Protalix BioTherapeutics And 2 Other Promising Penny Stocks

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?

iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025

PLX: 2024 Results

Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ...

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

3 US Penny Stocks With Market Caps Under $400M To Watch

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

PLX: Revisiting the Thesis

US Penny Stocks: Arbe Robotics And 2 More Promising Picks

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Performance Overview